HighVista Strategies LLC Sells 58,436 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

HighVista Strategies LLC lessened its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 58.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,856 shares of the company’s stock after selling 58,436 shares during the period. HighVista Strategies LLC owned approximately 0.05% of IDEAYA Biosciences worth $1,434,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDYA. Ameritas Investment Partners Inc. raised its position in IDEAYA Biosciences by 5.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $288,000 after purchasing an additional 332 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of IDEAYA Biosciences by 4.4% during the 1st quarter. Principal Financial Group Inc. now owns 15,275 shares of the company’s stock worth $670,000 after buying an additional 648 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in IDEAYA Biosciences by 38.4% in the second quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after buying an additional 927 shares in the last quarter. Covestor Ltd grew its position in IDEAYA Biosciences by 9,225.0% in the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after acquiring an additional 1,107 shares during the last quarter. Finally, Quest Partners LLC bought a new position in IDEAYA Biosciences in the second quarter valued at about $41,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA opened at $35.00 on Monday. The company has a market capitalization of $2.65 billion, a PE ratio of -17.41 and a beta of 0.84. IDEAYA Biosciences, Inc. has a fifty-two week low of $23.41 and a fifty-two week high of $47.74. The company has a 50 day simple moving average of $38.92 and a two-hundred day simple moving average of $39.66.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same quarter last year, the firm earned ($0.50) EPS. Research analysts predict that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current year.

Wall Street Analysts Forecast Growth

IDYA has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. JPMorgan Chase & Co. cut their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Wedbush reiterated an “outperform” rating and issued a $54.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, August 7th. Finally, Mizuho assumed coverage on IDEAYA Biosciences in a report on Monday, July 8th. They set an “outperform” rating and a $50.00 price objective on the stock. Twelve equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $56.20.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.